The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2017 | Changing epigenetic markers in CLL patients on ibrutinib
Katherine Holmes, PhD from St James’s University Hospital, Leeds, UK provides an outline of her work involving the detection of changing epigenetic markers in chronic lymphocytic leukemia (CLL) cells during treatment with ibrutinib. Dr Holmes hopes that by studying epigenetic markers which lead to active transcription or repression of certain genes, it is possible to determine disease relapse or predict outcome of drug treatment. The next step is to study the epigenetic landscape of CLL cells from patients on different therapies to compare markers, which could also aid in predicting patient outcomes. This interview was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.
